Quick Answer
Pasithea Therapeutics Corp. reported Total Revenue of $486.6 thousand for fiscal year 2022.
Pasithea Therapeutics Corp. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | $486.6K +3130.4% |
$15.1K | — |
| Net Income | -$20.43M -46.9% |
-$13.90M +12.9% |
-$15.96M -14.5% |
-$13.94M -541.2% |
-$2.17M | — |
| Diluted EPS | -$2.91 +77.1% |
-$12.69 | — | -$0.53 -152.4% |
-$0.21 | — |
| Total Assets | $60.24M +275.0% |
$16.06M -38.5% |
$26.12M -42.2% |
$45.18M -15.3% |
$53.32M +21403.9% |
$248.0K |
| Cash and Equivalents | $55.16M +696.8% |
$6.92M -57.6% |
$16.33M -50.6% |
$33.09M -37.5% |
$52.97M +21638.8% |
$243.7K |
| Stockholders Equity | $55.22M +273.5% |
$14.78M -36.8% |
$23.40M -44.9% |
$42.50M -17.4% |
$51.42M +21204.9% |
$241.4K |
| R&D Expense | $7.98M +10.9% |
$7.20M -11.1% |
$8.10M +203.9% |
$2.67M | — | — |
| Operating Income | -$20.86M -46.4% |
-$14.25M +10.8% |
-$15.98M -26.9% |
-$12.59M -179.3% |
-$4.51M | — |
| Gross Profit | — | — | — | — | -$2.2K | — |
| Shares Outstanding | 23.09M +1556.1% |
1.39M +33.9% |
1.04M -20.0% |
1.30M -94.3% |
23.01M +208.0% |
7.47M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2022 | $218.6K | — | +1509.7% |
| Net Income | September 30, 2025 | -$3.04M | -1.3% | +18.3% |
| Diluted EPS | September 30, 2025 | -$0.41 | +85.7% | +37.9% |
| Total Assets | September 30, 2025 | $13.63M | -26.9% | -19.9% |
| Cash and Equivalents | September 30, 2025 | $4.12M | -56.0% | -42.9% |
| Stockholders Equity | September 30, 2025 | $12.21M | -31.5% | -19.6% |
| R&D Expense | September 30, 2025 | $1.36M | -14.1% | -36.8% |
| Operating Income | September 30, 2025 | -$3.11M | -3.5% | +18.4% |
| Gross Profit | September 30, 2022 | $132.1K | — | +8793.6% |
| Shares Outstanding | September 30, 2025 | 7.44M | +612.4% | +0.0% |
- Pasithea Therapeutics Corp. reported Total Revenue of $486.6 thousand for fiscal year 2022.
- Pasithea Therapeutics Corp. showed an increase of +3130.4% in Total Revenue compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Net Income of -$20.43 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed a decrease of -46.9% in Net Income compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Diluted EPS of $2.91 per share (loss) for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +77.1% in Diluted EPS compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Total Assets of $60.24 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +275.0% in Total Assets compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Cash and Equivalents of $55.16 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +696.8% in Cash and Equivalents compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Stockholders Equity of $55.22 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +273.5% in Stockholders Equity compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported R&D Expense of $7.98 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +10.9% in R&D Expense compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Operating Income of -$20.86 million for fiscal year 2025.
- Pasithea Therapeutics Corp. showed a decrease of -46.4% in Operating Income compared to the prior fiscal year.
- Pasithea Therapeutics Corp. reported Gross Profit of -$2.2 thousand for fiscal year 2021.
- Pasithea Therapeutics Corp. reported Shares Outstanding of 23.09 million shares for fiscal year 2025.
- Pasithea Therapeutics Corp. showed an increase of +1556.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: